Conformis, Inc. (CFMS) News

Conformis, Inc. (CFMS): $0.88

-0.01 (-1.47%)

POWR Rating

Component Grades













Filter CFMS News Items

CFMS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CFMS News Highlights

  • For CFMS, its 30 day story count is now at 6.
  • Over the past 16 days, the trend for CFMS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about CFMS are IR, CR and SAFE.

Latest CFMS News From Around the Web

Below are the latest news stories about Conformis Inc that investors may wish to consider to help them evaluate CFMS as an investment opportunity.

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Friday Morning

It's the end of the week but investors can't relax just yet and that's why we have a list of the biggest pre-market movers for Friday.

William White on InvestorPlace | April 23, 2021

Conformis Announces Achievement of Third Milestone Under Development and License Agreements

BILLERICA, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received 510(k) clearance by the U.S. Food and Drug Administration for patient-specific instrumentation (“PSI”) developed by the Company under its License Agreement and Development Agreement with Howmedica Osteonics Corp., a wholly owned subsidiary of Stryker Corporation also known as Stryker Orthopaedics. With the clearance of this PSI system, which is designed for use with Stryker’s Triathlon® Total Knee System, the Company has achieved the third of three milestones under the agreements and will receive $11.0 million from Stryker. “With the recent FDA clearance, we are pleased to have attained the last milestone of our project and to report the successful conclusion of our joint ...

Yahoo | April 22, 2021

Conformis Announces License Agreement with Paragon 28

Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to ExpandBILLERICA, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a license agreement with Paragon 28, Inc., granting Paragon 28 a non-exclusive license under a subset of Conformis’ U.S. patents for the use of patient-specific instruments with off-the-shelf implants in Paragon 28’s APEX 3D™ Total Ankle Replacement System. “We are pleased to reach this agreement with Paragon 28, enabling it to incorporate our patient-specific instrument technology in its anticipated total ankle replacement offering,” said Mark Augusti, President and Chief Executive Officer. “We believe that this latest license agreement further demonstrates the broad a...

Yahoo | April 19, 2021

STERIS (STE) Hits a New 52-Week High: What's Driving It?

Investors are optimistic about STERIS (STE) backed by elevated consumer demand and strong segmental growth in third-quarter fiscal 2021.

Yahoo | April 19, 2021

Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE

Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.

Yahoo | April 16, 2021

Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021

BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Wednesday, May 5, 2021, at 4:30 p.m. Eastern Time to discuss the financial results and to provide a business update. The webcast will be live at: To attend by telephone, please use the information below for dial-in access. When prompted on dial-in, please utilize conference ID: 8727027.Participant conference numbers (877) 809-6331 (U.S./Canada) and (615) 247-0224 (International).Please dial in at...

Yahoo | April 7, 2021

Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System

Orthofix's (OFIX) CONSTRUX Mini Ti Spacer System, designed with nanoscale surface is the first 3D-printed titanium interbody, was launched to enhance ACDF procedures.

Yahoo | April 6, 2021

Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay.BILLERICA, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that an independent, retrospective review of hospital data has concluded that Conformis iTotal® knee replacement technology is more cost-effective than leading traditional, off-the-shelf implants. Importantly, this study was independently performed with no sponsorship or funding from Conformis. The new abstract was presented by authors at the Orthopaedic Research Society 2021 Annual Meeting (ORS 2021 Annual Meeting), held in February 2021: Custom-designed total knee...

Yahoo | March 17, 2021

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line.

Yahoo | March 16, 2021

Conformis (NASDAQ:CFMS) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Conformis (NASDAQ:CFMS) released its quarterly earnings results on Wednesday. The medical instruments supplier reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.02, Fidelity Earnings reports. Conformis had a negative net margin of 32.11% and a negative return on equity of 174.01%. CFMS opened at $1.01 on Thursday. The […]

Transcript Daily | March 4, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6516 seconds.